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Abstract
Introduction: We report a rare case of gastrointestinal perforation following dacarbazine infusion for metastatic
melanoma. The condition is attributed to a responding malignant melanoma in the gastrointestinal tract.
Case presentation: A 52-year-old Caucasian man presented with abdominal pain and distension, malaise, night
sweats, dysphagia and early satiety. A computed tomography scan showed massive ascites, lymphadenopathy and
liver lesions suspect for metastases. An upper gastrointestinal endoscopy was performed and revealed multiple
dark lesions of 5 mm to 10 mm in his stomach and duodenum.
When his skin was re-examined, an irregular pigmented lesion over the left clavicle measuring 15 mm × 8 mm
with partial depigmentation was found. Histological examination of a duodenal lesion was consistent with a diag-
nosis of metastatic melanoma. The patient deteriorated and his level of lactate dehydrogenase rapidly increased.
The patient was started on systemic treatment with dacarbazine 800 mg/m
2 every three weeks and he was dis-
charged one day after the first dose. On the sixth day he was readmitted with severe abdominal pain. A chest X-
ray showed the presence of free intraperitoneal air that was consistent with gastrointestinal perforation. His lactate
dehydrogenase level had fallen from 6969U/L to 1827U/L, supporting the conclusion that the response of gastroin-
testinal metastases to dacarbazine had resulted in the perforation of the patient’s bowel wall. A laparotomy was
discussed with the patient and his family but he decided to go home with symptomatic treatment. He died 11
days later.
Conclusion: Melanoma can originate in, as well as metastasize to, the gastrointestinal tract. Gastrointestinal
perforations due to responding tumors are a well-known complication of systemic treatment of gastrointestinal
lymphomas. However, as the response rate of metastatic melanoma to dacarbazine is only 10% to 20%, and
responses are usually only partial, perforation due to treatment response in metastatic melanoma is rare.
Medical oncologists should be aware of the risk of bowel perforation after starting cytotoxic chemotherapy on
patients with gastrointestinal metastases.
Introduction
The incidence of melanoma is increasing worldwide. In
The Netherlands 19.4 cases per 100,000 persons were
diagnosed in 2005. For the treatment of widespread
metastatic diseases, single agent dacarbazine (DTIC)
chemotherapy is still the standard of care. Combination
regimens with other cytotoxic agents, cytokines and tyr-
osine kinase inhibitors do not result in a survival benefit
[1-3].
Treatment with high-dose interleukin-2 (IL-2) has
induced a durable complete remission in a minority of
patients with metastatic melanoma, but this treatment is
associated with severe toxicity and it is not widely avail-
able [4].
Treatment with dacarbazine results in response rates
of 10% to 20%. Responses are usually partial and gener-
ally last for only four to six months, although prolonged
remissions are occasionally seen. A survival benefit of
treatment with dacarbazine over best supportive care
has not been proven definitively [5]. Compared to other
cytotoxic agents, dacarbazine is relatively well tolerated.
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Case presentation
In November 2007, a 52-year-old Caucasian man of
Dutch origin presented with upper abdominal pain,
anorexia, nausea, dyspnea on exertion, and a general
decline in condition for the past few weeks. His medi-
cal history revealed a subarachnoid hemorrhage eight
years prior to presentation, from which he recovered
completely, and essential hypertension that was well-
controlled.
On physical examination, a lymphadenopathy in the
patient’s left axilla and neck was found, in combination
with a distended abdomen with shifting dullness and an
enlarged irregular liver. Laboratory tests showed a slight
leukocytosis and thrombocytosis, normal haemoglobin,
creatinine and electrolytes levels, a lactate dehydrogen-
ase (LDH) level of 373IU/L that increased to 6969IU/L
in eight days, normal alkaline phosphate, normal transa-
minases and bilirubins. A computed tomography (CT)
scan of his chest and abdomen revealed lymphadenopa-
thy in the mediastinum, lung hili and left axilla, as well
as ascites with an omental cake and multiple lesions in
an enlarged liver. Ascitic fluid was sent to pathology,
and a gastroduodenoscopy was also performed. Multiple
dark gastric and duodenal lesions were found, which
were suspect for metastatic melanoma or Kaposi’ss a r -
coma (Figure 1). A biopsy of one of these lesions was
consistent with melanoma (Figure 2), as was the cytolo-
gical analysis of the ascitic fluid.
Subsequently, on re-examination of the skin, a 1.5 cm
irregular lesion over the left clavicle was found. The
lesion was partially pigmented and partially depigmen-
ted, which was consistent with a melanoma in regres-
sion (Figure 3).
Two days after an uncomplicated paracentesis, our
patient received 1560 mg (800 mg/m
2) dacarbazine
intravenously. He was discharged the next day.
Five days after chemotherapy he was readmitted with
severe abdominal pain. On physical examination, an
acute abdomen was found. A chest X-ray showed the
presence of free intraperitoneal air (Figure 4) and a clin-
ical diagnosis of gastrointestinal perforation was made.
His serum LDH level had fallen to 1827IU/L. A naso-
gastric tube was given and the patient was started on
broad spectrum antibiotics. The benefits and risks of
laparotomy were discussed with the patient and his
family, and he decided to go home with supportive care.
He died 11 days after the diagnosis of gastrointestinal
perforation was made.
Discussion
Melanoma can originate anywhere in the digestive tract,
but the majority of digestive tract lesions are metastatic
Figure 1 Upper gastrointestinal endoscopy showing multiple
dark duodenal lesions measuring 5 mm to 10 mm.
Figure 2 Histological examination of a duodenal lesion, Melan
A staining.
Figure 3 Pigmented skin lesion over the left clavicle measuring
15 mm × 8 mm with partial depigmentation consistent with a
melanoma in regression.
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when, as in this case, regression has occurred. In
patients with end stage melanoma, gastric metastases
and small bowel metastases are quite common. In two
large autopsy series, gastric metastases were found in
about 20% of the patients studied, and small bowel
metastases in 35.6% and 58% of the patients [6,7].
Differentiation between a primary gastrointestinal tract
lesion and metastasis from an occult cutaneous mela-
noma can be difficult in cases with solitary gastrointest-
inal localization. However, due to the lack of
convincingly effective adjuvant regimens for melanoma,
the clinical consequences are marginal.
Surgery for melanoma lesions that are metastatic to
the gastrointestinal tract is quite effective for controlling
symptoms but it rarely leads to long-term survival [8,9].
The systemic treatment of metastatic disease has been
met with limited success. Over the decades, single-agent
treatment with dacarbazin has remained the standard of
care. An incentive for using this drug even in the end
stage of the disease is its limited toxicity, with easily
controllable nausea as its main clinical side effect. The
generally mild hematological toxicity of dacarbazine
compares favorably to that of drugs used in other
advanced stages of cancer [10]. Although the response
rate is low, prolonged remissions are sometimes
achieved, which makes treatment worthwhile.
Perforation of a gastrointestinal tumor as a result of che-
motherapy is rare, as remissions are usually partial and
occur gradually. An exception in this regard is intra-
abdominal lymphoma. This tumor is highly sensitive to
cytotoxic therapy and responds with rapid necrosis.
Abdominal non-Hodgkin’s lymphoma in children, with
otherwise favorable prognosis, is associated with a very
poor outcome if gastrointestinal perforation occurs [11,12].
We could only identify one other case of fatal gastro-
intestinal perforation in a patient with metastatic mela-
noma during treatment with dacarbazine, but bowel
perforation was not attributed to chemotherapy by the
authors [10]. In our patient, perforation was ascribed to
responding gastrointestinal metastases. A recent gastro-
intestinal endoscopy had revealed multiple metastases
and no peptic ulcers. Our patient had not been using
non-steroidal anti-inflammatory drugs (NSAIDs), which
makes perforation of a gastric or duodenal ulcer unli-
kely. Furthermore, his LDH level had fallen dramatically,
thus indicating his fast response to chemotherapy.
Conclusion
Chemotherapy in end stage melanoma is aimed at a
rarely achievable goal of prolonged remission in the
context of limited toxicity. In the presence of extensive
digestive tract involvement, a remission could lead to
perforation, resulting in excess toxicity and probably
death. When perforation is recognized as a possible
threat, a prolonged administration of the drug in its oral
formulation might be advisable. This does not seem to
compromise treatment efficacy [10].
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